← Back to Guidelines

2012 ACCF/AHA/HRS Device-Based Therapy Guidelines

Clinical Quick Reference — Pacing, ICD, and CRT Management

Published: Journal of the American College of Cardiology (2013)
Societies: ACCF / AHA / HRS (focused update of 2008 guidelines)
DOI: 10.1016/j.jacc.2012.11.007
View Full Guideline PDF

What's New in 2012

This focused update incorporates pivotal trials and new evidence. Key changes:

Major Updates

  • CRT Expansion: Class I for LVEF ≤35%, sinus rhythm, LBBB ≥150 ms, NYHA II–IV
  • ICD Primary Prevention: Refined LVEF thresholds (≥40 days post-MI, ≤30% for non-ischemic)
  • Remote Monitoring: NEW section on transtelephonic and wireless remote monitoring
  • Pediatric ICDs: Expanded coverage for genetic conditions and congenital heart disease

Pacing for Sinus Node Dysfunction

SND presents with bradycardia, bradycardia-tachycardia syndrome, or chronotropic incompetence. Treatment is indicated for symptomatic patients.

Class I: Permanent Pacing Indicated

IndicationDetailsCOR
Symptomatic bradycardia Documented symptomatic bradycardia with pauses ≥3 seconds or sinus rate <40 bpm with clear symptom correlation 1
Chronotropic incompetence Symptomatic inability to achieve adequate HR with exertion 1
Symptomatic bradycardia + required drug therapy Bradycardia due to essential cardiac medications (beta-blockers, rate-limiting CCBs) 1

Class II & III

Class IIb: SND with HR 40–50 bpm if clear symptom-rhythm correlation. Class III: Asymptomatic SND.
Pearl: Always correlate symptoms with bradycardia. Use Holter or event monitoring if correlation is unclear. Asymptomatic SND does not require pacing.

Pacing for Atrioventricular Block

Management depends on degree, location (AV nodal vs. infra-Hisian), and symptom status.

First-Degree AV Block

No Pacing

  • Not indicated even if symptomatic. Class III.

Second-Degree Type I (Wenckebach)

Generally Not Indicated

  • Benign prognosis; pacing not recommended unless symptomatic at infra-Hisian level. Class III.

Second-Degree Type II & Advanced 2nd Degree

Pacing Indicated

  • Type II symptomatic: Pacing indicated for symptoms (syncope, dyspnea). Class I.
  • Asymptomatic infra-Hisian: Pacing indicated even without symptoms if proven infra-Hisian block. Class I.
  • Advanced 2nd-degree: Pacing indicated at any site. Class I.

Third-Degree AV Block

Pacing Clearly Indicated

  • Persistent 3rd-degree post-MI: Permanent ventricular pacing. Class I.
  • Transient infra-Hisian block + bundle-branch block: Permanent pacing. Class I.
  • Chronic 3rd-degree with wide QRS (infra-Hisian): Pacing indicated regardless of symptoms. Class I.

AV Block Decision Tree

Step 1: Narrow QRS (AV nodal) or wide QRS (infra-Hisian)?
Narrow QRS: May trial drugs before pacing. Wide QRS: Pacing generally indicated.
Step 2: Are symptoms present (syncope, dyspnea)?
YES → Pacing indicated (Class I)
NO but structural disease → Pacing reasonable (Class IIa)
Pearl: Infra-Hisian block (wide QRS, HV >100 ms) carries high risk of sudden progression and merits pacing even if asymptomatic. Use EPS if site is unclear.

Pacing for Special Conditions

Cardiac Transplantation

Class I: Permanent pacing is indicated for persistent bradycardia not expected to resolve. Class I, LOE: C.

Hypertrophic Cardiomyopathy (HCM)

Class IIa: Permanent pacing may be considered for medically refractory LVOT obstruction with symptoms. Class IIa, LOE: A.

Neuromuscular Diseases

Key Point: Progressive AV block is common in myotonic dystrophy and Emery-Dreifuss dystrophy. Anticipate need for pacing and follow closely.

Sleep Apnea

Note: Pacing does NOT treat sleep apnea. PAP therapy is first-line. Patients with OSA and symptomatic bradycardia may benefit from pacemaker therapy.

Cardiac Resynchronization Therapy (CRT)

CRT is indicated for LVEF ≤35%, QRS ≥120 ms (preferably LBBB), and NYHA II–IV symptoms on optimal medical therapy. Available as CRT-P (pacemaker) or CRT-D (defibrillator).

Class I Recommendations

PopulationKey CriteriaCOR
Ischemic or non-ischemic DCM LVEF ≤35%, sinus rhythm, LBBB ≥150 ms, NYHA II/III/IV on GDMT 1
NYHA Class II LVEF ≤35%, LBBB ≥150 ms (LOE: A ischemic, B non-ischemic) 1

Class IIa: May Be Beneficial

CRT Considered

  • LVEF ≤35%, non-LBBB, QRS 120–149 ms, NYHA II–IV: Class IIa, LOE: B
  • LVEF ≤30%, non-ischemic DCM, LBBB ≥150 ms, NYHA I: Class IIa, LOE: B
  • Atrial fibrillation with LVEF ≤35, requiring pacing ≥40%: Class IIa, LOE: C

Class IIb: May Be Considered

  • LVEF <30%, ischemic, LBBB ≥150 ms, NYHA I: Class IIb, LOE: C
  • LVEF <30%, non-ischemic, non-LBBB, QRS 120–149 ms, NYHA II: Class IIb, LOE: C

Class III: Not Indicated

Do Not Use CRT

  • NYHA I/II + non-LBBB + QRS <120 ms: Not indicated. Class III, LOE: B
  • Comorbidity limiting survival to <1 year: Not indicated. Class III, LOE: C

CRT Candidacy Algorithm

Step 1: LVEF ≤35%?
NO: CRT not indicated (except rare LVEF 35–40% with HF/ICD)
YES: Continue
Step 2: QRS ≥120 ms with LBBB?
NO: Limit to Class IIb; reduced benefit
YES: Continue
Step 3: NYHA II–IV on optimal medical therapy?
Class I only (Class IIb if LVEF ≤30%, NYHA I)
CRT is Class I indicated. Choose CRT-P or CRT-D.

→ Open CRT Candidate Calculator | CRT Response Estimator

ICD — Primary Prevention of Sudden Cardiac Death

Primary prevention ICDs reduce SCD mortality in high-risk patients without prior ventricular arrhythmias. LVEF ≤35% is the cornerstone criterion.

Class I: ICD Clearly Indicated

Definite Indications

  • Prior cardiac arrest (VF/VT): After reversible causes excluded. LOE: A
  • Structural disease + spontaneous sustained VT: LOE: B
  • Ischemic cardiomyopathy: LVEF ≤30%, prior MI ≥40 days, NSVT on Holter, inducible VT on EPS (MADIT II criteria). LOE: A
  • Nonischemic DCM: LVEF ≤35%, NYHA II–III (SCD-HeFT). LOE: B

Class IIa: ICD Reasonable

IndicationLOECOR
Unexplained syncope, reduced LVEF, inducible VT: ICD reasonable. LOE: C C 2a
Sustained VT, normal or near-normal EF: ICD reasonable. LOE: B B 2a
HCM with ≥1 major SCD risk factor: ICD reasonable (unexplained syncope, family hx SCD, LVOT gradient, wall thickness ≥30 mm). LOE: C C 2a
ARVC with risk factors: ICD reasonable (unexplained syncope, NSVT, family hx SCD, extensive RV involvement). LOE: C C 2a

Class IIb: May Be Considered

  • Nonischemic DCM, LVEF ≤35%, NYHA Class I: LOE: C
  • Long-QT syndrome, high-risk, recurrent syncope: LOE: B
  • Brugada syndrome with high-risk features: LOE: C
  • CPVT with syncope despite beta-blockers: LOE: C
Key Takeaway: LVEF ≤35% (≤30% in some populations) at least 40 days post-MI or in non-ischemic cardiomyopathy is the main driver for primary prevention ICD. → Use MADIT Risk Calculator

ICD — Secondary Prevention

Secondary prevention ICDs are indicated for survivors of cardiac arrest or sustained VT with structural disease.

Class I: ICD Clearly Indicated

Definite Indications

  • Cardiac arrest from VF or hemodynamically unstable VT: After reversible causes excluded. LOE: A
  • Structural disease + spontaneous sustained VT: Whether hemodynamically stable or unstable. LOE: B
  • Syncope of undetermined origin + inducible VT: With structural disease present. LOE: C

Specific Disease States

ConditionICD RecommendationCOR
CAD with prior MI + sustained VT/VF Class I indicated 1
Nonischemic DCM + VT/VF, LVEF <35% Class I indicated 1
Long-QT + recurrent syncope despite BBs Class IIa reasonable 2a
Brugada syndrome + documented VT/VF or high-risk Class IIa reasonable 2a
CPVT + recurrent syncope despite BBs Class IIb may be considered 2b
Key Takeaway: All cardiac arrest survivors from VT/VF (barring reversible cause) or patients with sustained VT and structural disease should receive an ICD.

Device Selection and Lead Management

Pacemaker Type Selection

DeviceIndicationKey Advantage
Single-chamber atrial SND without AV block; preserve AV synchrony Lower cost; simpler; maintains AV conduction
Single-chamber ventricular Chronic AF; VVI pacing appropriate Appropriate for AF; rate response available
Dual-chamber AV block; SND with need for AV sync; improve hemodynamics Maintains AV synchrony; better QOL; reduces AF risk
CRT-P or CRT-D LVEF ≤35%, LBBB, QRS ≥120 ms, NYHA II–IV Biventricular pacing improves EF, reduces HF admissions, improves survival

Lead Management

Lead Longevity: Modern leads function 10–15+ years. Lead extraction may be needed for infection, failure, recall, or vascular obstruction. Always balance extraction risk against risk of leaving a failed lead.

Indications for Lead Extraction

  • Device infection or endocarditis
  • Lead fracture or insulation failure with loss of function
  • Lead recall or safety advisory
  • Vascular access obstruction preventing new lead placement
  • Transvenous lead system dysfunction requiring revision

Pacemaker and ICD Follow-Up

Routine follow-up ensures early detection of battery depletion, lead problems, and appropriate device function.

Follow-Up Schedule

DeviceIntervalFrequency
Pacemaker (single/dual-chamber) 1st month post-implant Every 2 weeks
2nd–36th month Every 8 weeks
37th month–battery failure Every 4 weeks
ICD 1st month post-implant Every 2 weeks
2nd–6th month Every 4 weeks
7th–36th month Every 8 weeks
37th month–battery failure Every 4 weeks

Remote Monitoring (2012 Update)

Transtelephonic Monitoring (TTM) & Wireless Remote Monitoring: Increasingly used to supplement in-office visits. Allows remote interrogation of rhythm, pacing thresholds, battery, lead integrity, and early detection of clinically actionable events (AF, arrhythmias, lead failures). Hybrid approaches (remote + select office visits) improve safety and convenience without compromising clinical outcomes.

Assessment at Each Visit

Required Elements

  • Patient clinical status and device tolerance
  • ECG with capture, sensing, AV intervals documented
  • Magnet rate and battery status
  • Lead impedance, thresholds, and sensing
  • Programmed settings appropriateness
  • Stored events review (arrhythmias, shocks, mode switches)
  • Patient education and counseling on device restrictions (driving, MRI, security, etc.)

Special Populations

Elderly Patients

Key Point: Age is not a contraindication. However, in elderly with multiple comorbidities, balance procedural risk and longevity against device benefit. Shared decision-making is essential.

Congenital Heart Disease

Pediatric Populations: ICD indications similar to adults, but threshold for intervention may be lower due to long life expectancy. SCD prevention is particularly important in young patients.

Heart Transplant Candidates

Device Use in Transplantation

  • ICDs can bridge to transplantation in SCD-at-risk patients awaiting donor organs
  • Mechanical circulatory support (VAD) increasingly used as destination therapy or bridge
  • Some post-transplant patients develop SND or AV block requiring pacemaker

Pregnancy

Pregnancy with Device Therapy: Women can safely become pregnant. Requires coordination between obstetrics, cardiology, and EP. Optimize device settings and monitor closely for arrhythmias. Remote monitoring is particularly valuable.

Neuromuscular & Genetic Diseases

Progressive Conduction Disease: Myotonic dystrophy, Emery-Dreifuss, and related conditions have high risk of progressive AV block. Anticipate early device need and follow closely.

Sleep Apnea

Note: Pacing does NOT treat sleep apnea. PAP therapy is first-line. Patients with OSA + symptomatic bradycardia may benefit from pacemaker therapy.

Related Calculators

Use these SattiMD calculators to support device therapy decision-making: